PROLI NONOate
Based on 1 Customer Validation
PROLI NONOate is a NO donor. It spontaneously dissociates in a pH-dependent, first-order process with a half-life of 1.8 seconds at 37°C (pH 7.4) to liberate 2 moles of NO per mole of parent compound.
For research use only. We do not sell to patients.
- Purity : 98%
- CAS No.: 178948-42-0
- Formula: C5H7N3Na2O4
- Molecular Weight:219.11
-
Storage:
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Biological Activity
Description
Chemical Information
-
CAS No. 178948-42-0
-
Appearance Solid
-
Molecular Weight 219.11
-
Formula C5H7N3Na2O4
-
Color White to off-white
-
SMILES
O=C(O[Na])[C@H]1N(/[N+]([O-])=N/O[Na])CCC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (456.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.5639 mL | 22.8196 mL | 45.6392 mL | 114.0979 mL |
| 5 mM | 0.9128 mL | 4.5639 mL | 9.1278 mL | 22.8196 mL | |
| 10 mM | 0.4564 mL | 2.2820 mL | 4.5639 mL | 11.4098 mL | |
| 15 mM | 0.3043 mL | 1.5213 mL | 3.0426 mL | 7.6065 mL | |
| 20 mM | 0.2282 mL | 1.1410 mL | 2.2820 mL | 5.7049 mL | |
| 25 mM | 0.1826 mL | 0.9128 mL | 1.8256 mL | 4.5639 mL | |
| 30 mM | 0.1521 mL | 0.7607 mL | 1.5213 mL | 3.8033 mL | |
| 40 mM | 0.1141 mL | 0.5705 mL | 1.1410 mL | 2.8524 mL | |
| 50 mM | 0.0913 mL | 0.4564 mL | 0.9128 mL | 2.2820 mL | |
| 60 mM | 0.0761 mL | 0.3803 mL | 0.7607 mL | 1.9016 mL | |
| 80 mM | 0.0570 mL | 0.2852 mL | 0.5705 mL | 1.4262 mL | |
| 100 mM | 0.0456 mL | 0.2282 mL | 0.4564 mL | 1.1410 mL |